期刊
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
卷 61, 期 6, 页码 836-841出版社
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
DOI: 10.1080/01635580903285056
关键词
-
资金
- NCI NIH HHS [R01 CA 78809, R01 CA101039, R01 CA 101039, R01 CA120451-05, R01 CA078809, R01 CA078809-10, R01 CA 120451, R01 CA101039-05, R01 CA120451] Funding Source: Medline
- NIDDK NIH HHS [P50 DK065303] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA120451, R01CA078809, R01CA101039] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065303] Funding Source: NIH RePORTER
The prevention of prostate cancer (PCa) is a crucial medical challenge in developed countries. PCa remains surrounded by puzzles in spite of the considerable progress in research, diagnosis, and treatment. It is an ideal target for chemoprevention, as clinically significant PCa usually requires more than two decades for development. Green tea and its major constituent epigallocatechin gallate (EGCG) have been extensively studied as a potential treatment for a variety of diseases including cancer. In this review, we highlight the evidences of green tea polyphenols from preclinical and clinical studies in the chemoprevention/chemotherapy of PCa.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据